IN2014KN01714A - - Google Patents
Info
- Publication number
- IN2014KN01714A IN2014KN01714A IN1714KON2014A IN2014KN01714A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A IN 1714KON2014 A IN1714KON2014 A IN 1714KON2014A IN 2014KN01714 A IN2014KN01714 A IN 2014KN01714A
- Authority
- IN
- India
- Prior art keywords
- antibody
- cancer
- amino acid
- acid sequence
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012035342 | 2012-02-21 | ||
| PCT/JP2013/054312 WO2013125630A1 (fr) | 2012-02-21 | 2013-02-21 | Composition pharmaceutique pour le traitement et/ou la prévention du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN01714A true IN2014KN01714A (fr) | 2015-10-23 |
Family
ID=49005808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1714KON2014 IN2014KN01714A (fr) | 2012-02-21 | 2013-02-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9260513B2 (fr) |
| EP (1) | EP2818481B1 (fr) |
| JP (1) | JP6187257B2 (fr) |
| KR (1) | KR102005308B1 (fr) |
| CN (1) | CN104114581B (fr) |
| AU (1) | AU2013223137B2 (fr) |
| BR (1) | BR112014021099A2 (fr) |
| CA (1) | CA2864999C (fr) |
| DK (1) | DK2818481T3 (fr) |
| ES (1) | ES2749672T3 (fr) |
| HU (1) | HUE046788T2 (fr) |
| IN (1) | IN2014KN01714A (fr) |
| MX (1) | MX363136B (fr) |
| PL (1) | PL2818481T3 (fr) |
| PT (1) | PT2818481T (fr) |
| RU (1) | RU2639522C2 (fr) |
| WO (1) | WO2013125630A1 (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX337991B (es) | 2008-08-05 | 2016-03-30 | Toray Industries | Metodo para detectar cancer. |
| DK2322221T3 (da) | 2008-08-05 | 2014-09-01 | Toray Industries | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
| AU2011211699B2 (en) * | 2010-02-04 | 2015-01-22 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| BR112014002619A2 (pt) * | 2011-08-04 | 2018-10-09 | Toray Industries, Inc | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica |
| ES2629061T3 (es) * | 2011-08-04 | 2017-08-07 | Toray Industries, Inc. | Método para la detección de cáncer pancreático |
| MX357505B (es) | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| PT2832365T (pt) * | 2012-03-30 | 2018-01-24 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático |
| US9428581B2 (en) | 2012-03-30 | 2016-08-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
| WO2014014082A1 (fr) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | Procédé de détection de cancer |
| CA2879185C (fr) | 2012-07-19 | 2021-08-24 | Toray Industries, Inc. | Procede de detection de cancer |
| CA2918989C (fr) | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Composition pharmaceutique pour le traitement et/ou la prevention du cancer |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| WO2018079740A1 (fr) | 2016-10-28 | 2018-05-03 | 東レ株式会社 | Composition pharmaceutique pour le traitement et/ou la prévention du cancer |
| WO2019189780A1 (fr) | 2018-03-30 | 2019-10-03 | 東レ株式会社 | Composition pharmaceutique pour le traitement et/ou la prévention du cancer |
| EP3937984A1 (fr) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugués ciblant le her2 |
| JP2022537158A (ja) | 2019-06-13 | 2022-08-24 | ボルト バイオセラピューティクス、インコーポレーテッド | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
| EP4038053A1 (fr) | 2019-09-30 | 2022-08-10 | Bolt Biotherapeutics, Inc. | Immunoconjugués d'aminobenzazépine liés à des amides et leurs utilisations |
| EP4048315B1 (fr) | 2019-10-25 | 2025-03-12 | Bolt Biotherapeutics, Inc. | Immunoconjugués de thiénoazépine et leurs utilisations |
| JPWO2021182574A1 (fr) * | 2020-03-12 | 2021-09-16 | ||
| EP4119157A4 (fr) | 2020-03-12 | 2024-03-27 | Toray Industries, Inc. | Médicament pour le traitement et/ou la prévention du cancer |
| JP7797875B2 (ja) | 2020-03-12 | 2026-01-14 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CA3175127A1 (fr) * | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament pour le traitement et/ou la prevention du cancer |
| CA3175129A1 (fr) | 2020-03-12 | 2021-09-19 | Toray Industries, Inc. | Medicament pour le traitement et/ou la prevention du cancer |
| CA3176626A1 (fr) | 2020-05-08 | 2021-11-11 | David Dornan | Substrat pour elastase, immunoconjugues de liaison peptidique et leurs utilisations |
| MX2023001679A (es) | 2020-08-13 | 2023-02-22 | Bolt Biotherapeutics Inc | Inmunoconjugados de pirazolazepina y usos de estos. |
| EP4360648A4 (fr) | 2021-06-23 | 2025-10-08 | Toray Industries | Médicament pour le traitement et/ou la prévention du cancer |
| AU2022298240A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4378478A4 (fr) | 2021-07-27 | 2025-11-12 | Toray Industries | Médicament pour le traitement et/ou la prévention du cancer |
| KR20240042415A (ko) | 2021-07-27 | 2024-04-02 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| AU2022319362A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3230737A1 (fr) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Composition pharmaceutique pour le traitement et/ou la prevention du cancer |
| US20250000995A1 (en) | 2021-10-29 | 2025-01-02 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| AU2023329564A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CN119768181A (zh) | 2022-08-24 | 2025-04-04 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| JPWO2024043252A1 (fr) | 2022-08-24 | 2024-02-29 | ||
| CN119789868A (zh) | 2022-08-30 | 2025-04-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| AU2023334696A1 (en) | 2022-08-30 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| KR20250118852A (ko) | 2022-12-23 | 2025-08-06 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| WO2024173387A1 (fr) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Immunoconjugués d'aza-benzazépine et leurs utilisations |
| WO2024186626A1 (fr) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Immunoconjugués d'agonistes de sting aza-bicycliques et leurs utilisations |
| WO2024204325A1 (fr) | 2023-03-28 | 2024-10-03 | 東レ株式会社 | Procédé de détection de protéine de membrane cellulaire |
| EP4691490A1 (fr) | 2023-03-31 | 2026-02-11 | Toray Industries, Inc. | Composition pharmaceutique pour le traitement et/ou la prévention du cancer |
| JPWO2025058000A1 (fr) | 2023-09-13 | 2025-03-20 | ||
| WO2026055185A1 (fr) | 2024-09-04 | 2026-03-12 | Bolt Biotherapeutics, Inc. | Immunoconjugués agonistes sting et leurs utilisations |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE340590T1 (de) | 1994-07-13 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| SK14812000A3 (sk) | 1998-04-03 | 2001-08-06 | Chugai Seiyaku Kabushiki Kaisha | Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| TR200100916T2 (fr) | 1998-07-14 | 2002-06-21 | Corixa@@Corporation | |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| EP1187915A2 (fr) | 1999-04-02 | 2002-03-20 | Corixa Corporation | Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d'utilisation |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| JP2003528587A (ja) | 1999-10-29 | 2003-09-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ２７個のヒト分泌タンパク質 |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| AU2001261007A1 (en) | 2000-03-29 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| WO2002083070A2 (fr) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Composes pour l'ummunotherapie et le diagnostic du cancer du colon et methodes d'utilisation associees |
| AU2002311909A1 (en) | 2001-05-11 | 2002-11-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| AU2002309063B8 (en) | 2001-05-11 | 2008-04-24 | Kyowa Kirin Co., Ltd. | Artificial human chromosome containing human antibody lambda light chain gene |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20040258678A1 (en) | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP1572116A4 (fr) | 2002-11-26 | 2007-12-12 | Genentech Inc | Compositions et procedes destines au traitement de maladies de nature immune |
| WO2004076682A2 (fr) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Cibles destinees a reguler la croissance cellulaire et destinees a des methodes de diagnostic |
| AU2004235382A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing AML and MDS differential gene expression |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| WO2005116076A2 (fr) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Polypeptides specifiques aux tumeurs et leurs utilisations |
| ES2387809T3 (es) | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
| BRPI0509367A (pt) | 2004-03-30 | 2007-09-11 | Glaxo Group Ltd | anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico |
| WO2005100998A2 (fr) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer |
| WO2006002378A2 (fr) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determination de genes associes au cancer et de cibles therapeutiques utilisant des methodes de cytogenetique moleculaire |
| EP3698807A1 (fr) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Dosage fixe d'anticorps anti-her |
| AU2006214105A1 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| EP1869462B1 (fr) | 2005-03-11 | 2013-05-08 | Ciphergen Biosystems, Inc. | Biomarqueurs du cancer de l'ovaire et de l'endometre: la hepcidine |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| CA2642342A1 (fr) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, et procedes pour identifier, evaluer, prevenir et traiter un cancer |
| WO2008073162A2 (fr) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Sites d'acétylation de lysine |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2008031041A2 (fr) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Signature de gène de mélanome |
| WO2008059252A2 (fr) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Procédés et composition de récepteurs des lymphocytes t qui reconnaissent l'antigène 5t4 |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| NZ587706A (en) | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| DK2322221T3 (da) | 2008-08-05 | 2014-09-01 | Toray Industries | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
| MX337991B (es) | 2008-08-05 | 2016-03-30 | Toray Industries | Metodo para detectar cancer. |
| PL2324842T3 (pl) | 2008-08-05 | 2015-08-31 | Toray Industries | Środek indukujący odporność |
| BR112012003686B1 (pt) | 2009-08-19 | 2021-09-21 | Merck Patent Gmbh | Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo |
| KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
| AU2011211699B2 (en) * | 2010-02-04 | 2015-01-22 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| KR101871704B1 (ko) | 2010-02-04 | 2018-06-27 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| KR101842893B1 (ko) | 2010-02-04 | 2018-03-28 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| BR112012018951C8 (pt) | 2010-02-04 | 2020-06-23 | Toray Industries | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
| HUE040012T2 (hu) | 2010-02-04 | 2019-02-28 | Toray Industries | Gyógyászati ágens rák kezelésére és/vagy megelõzésére |
| JP5845899B2 (ja) | 2010-02-04 | 2016-01-20 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| WO2012005550A2 (fr) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | Composition pharmaceutique pour le traitement d'un carcinome de la vésicule biliaire et méthode d'inhibition de la croissance et des métastases d'un carcinome de la vésicule biliaire et le traitement d'un carcinome de la vésicule biliaire à l'aide de celle-ci |
| KR101576174B1 (ko) | 2010-07-26 | 2015-12-09 | 르 라보레또레 쎄르비에르 | 간암 요법을 위한 방법 및 조성물 |
| JP5545105B2 (ja) | 2010-08-04 | 2014-07-09 | 株式会社ジェイテクト | トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置 |
| ES2629061T3 (es) | 2011-08-04 | 2017-08-07 | Toray Industries, Inc. | Método para la detección de cáncer pancreático |
| PT2740796T (pt) | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| BR112014002619A2 (pt) | 2011-08-04 | 2018-10-09 | Toray Industries, Inc | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica |
| US9428581B2 (en) | 2012-03-30 | 2016-08-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
| PT2832365T (pt) | 2012-03-30 | 2018-01-24 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático |
-
2013
- 2013-02-21 IN IN1714KON2014 patent/IN2014KN01714A/en unknown
- 2013-02-21 KR KR1020147020831A patent/KR102005308B1/ko active Active
- 2013-02-21 PT PT137511598T patent/PT2818481T/pt unknown
- 2013-02-21 MX MX2014009747A patent/MX363136B/es unknown
- 2013-02-21 BR BR112014021099-3A patent/BR112014021099A2/pt not_active Application Discontinuation
- 2013-02-21 PL PL13751159T patent/PL2818481T3/pl unknown
- 2013-02-21 CA CA2864999A patent/CA2864999C/fr active Active
- 2013-02-21 DK DK13751159.8T patent/DK2818481T3/da active
- 2013-02-21 JP JP2013512279A patent/JP6187257B2/ja active Active
- 2013-02-21 RU RU2014138039A patent/RU2639522C2/ru active
- 2013-02-21 WO PCT/JP2013/054312 patent/WO2013125630A1/fr not_active Ceased
- 2013-02-21 AU AU2013223137A patent/AU2013223137B2/en active Active
- 2013-02-21 HU HUE13751159A patent/HUE046788T2/hu unknown
- 2013-02-21 CN CN201380009166.3A patent/CN104114581B/zh active Active
- 2013-02-21 EP EP13751159.8A patent/EP2818481B1/fr active Active
- 2013-02-21 ES ES13751159T patent/ES2749672T3/es active Active
- 2013-02-21 US US14/379,868 patent/US9260513B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2639522C2 (ru) | 2017-12-21 |
| PT2818481T (pt) | 2019-10-25 |
| AU2013223137A1 (en) | 2014-09-11 |
| RU2014138039A (ru) | 2016-04-10 |
| US20150044221A1 (en) | 2015-02-12 |
| BR112014021099A2 (pt) | 2020-12-01 |
| US9260513B2 (en) | 2016-02-16 |
| AU2013223137B2 (en) | 2017-10-19 |
| CA2864999C (fr) | 2020-06-30 |
| JPWO2013125630A1 (ja) | 2015-07-30 |
| DK2818481T3 (da) | 2019-10-14 |
| EP2818481A1 (fr) | 2014-12-31 |
| WO2013125630A1 (fr) | 2013-08-29 |
| CN104114581B (zh) | 2018-11-30 |
| CN104114581A (zh) | 2014-10-22 |
| MX2014009747A (es) | 2014-11-14 |
| ES2749672T3 (es) | 2020-03-23 |
| HUE046788T2 (hu) | 2020-03-30 |
| EP2818481B1 (fr) | 2019-08-07 |
| PL2818481T3 (pl) | 2020-02-28 |
| KR102005308B1 (ko) | 2019-07-30 |
| KR20140130670A (ko) | 2014-11-11 |
| EP2818481A4 (fr) | 2015-10-07 |
| CA2864999A1 (fr) | 2013-08-29 |
| JP6187257B2 (ja) | 2017-08-30 |
| MX363136B (es) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN01713A (fr) | ||
| IN2014KN01716A (fr) | ||
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| IN2014KN01715A (fr) | ||
| MX351682B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX358224B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado. | |
| MX2016001640A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| WO2017009843A3 (fr) | Compositions, articles de fabrication et procédés pour traiter le cancer | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| NZ761006A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| MY167232A (en) | Polypeptides binding to human complement c5 | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| IN2014DN09963A (fr) | ||
| GB201118201D0 (en) | Novel peptides | |
| MX2016008989A (es) | Fragmentos mutantes de ospa y metodos y usos relacionados con estos. | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2014039074A3 (fr) | Compositions thérapeutiques et méthodes associées |